PIMS launches advanced MICU and introduces Benralizumab therapy for severe asthma patients, improving quality of life.

Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. We conducted a multicenter, double-blind, phase 3 ...

The safety of benralizumab showed no “meaningful difference” compared with mepolizumab. Benralizumab only requires one monthly injection, while mepolizumab requires three. Benralizumab is ...

Benralizumab is noninferior to mepolizumab for the treatment of patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis receiving standard of care. Benralizumab is ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

Please provide your email address to receive an email when new articles are posted on . Benralizumab induces depletion of eosinophils and mepolizumab reduces activation. The study followed ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab for up to 2 years, with better outcomes in biologic-naive ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

Benralizumab comes as an injection which is available as a single dose prefilled syringe to be administered subcutaneously or just under the skin. • Benralizumab should be allowed to warm at ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...